| Literature DB >> 20186297 |
Adriana Lúcia Agnelli Meirelles-Costa1, Claudio José Caldas Bresciani, Rodrigo Oliva Perez, Barbara Helou Bresciani, Sheila Aparecida C Siqueira, Ivan Cecconello.
Abstract
INTRODUCTION: Gallbladder cancer, which is characterized by rapid progression and a poor prognosis, is a complex disease to treat. Unfortunately, little is known currently about its etiology or pathogenesis. A better understanding of its carcinogenesis and determining risk factors that lead to its development could help improve the available treatment options.Entities:
Keywords: Adenomyoma; Cholecystectomy; Cholelithiasis; Gallbladder neoplasms; Laparoscopic; Metaplasia
Mesh:
Year: 2010 PMID: 20186297 PMCID: PMC2827700 DOI: 10.1590/S1807-59322010000200005
Source DB: PubMed Journal: Clinics (Sao Paulo) ISSN: 1807-5932 Impact factor: 2.365
Frequency of the gallbladder histological alterations studied.
| Number of cases | Frequency | |
|---|---|---|
| Cholesterolosis | 305 | 18.1% |
| Acute cholecystitis | 174 | 10.3% |
| Xanthogranulomatous cholecystitis | 29 | 1.7% |
| Sclero-atrophic gallbladder | 20 | 1.2% |
| Hyperplasic polyp | 3 | 0.2% |
| Cholesterol polyp | 17 | 1.0% |
| Adenomyomatosis | 40 | 2.4% |
| Fibrosis | 12 | 0.7% |
| Gangrene | 23 | 1.4% |
| Abscess | 8 | 0.5% |
| Pyloric metaplasia | 72 | 4.3% |
| Intestinal metaplasia | 18 | 1.1% |
| Dysplasia | 4 | 0.2% |
| Cancer | 2 | 0.1% |
Analysis of the gallbladder histological alterations according to gender.
| Male n (%) | Female n (%) | p | |
|---|---|---|---|
| Cholesterolosis | 76 (16.9%) | 229 (18.5%) | 0.437 (P) |
| Acute cholecystitis | 80 (17.7%) | 94 (7.6%) | 0.001 (P) |
| Xanthogranulomatous cholecystitis | 5 (1.1%) | 24(1.9%) | 0.245 (P) |
| Sclero-atrophic gallbladder | 13 (2.9%) | 7 (0.6%) | 0.001 (P) |
| Hyperplasic polyp | 0 (0%) | 3 (0.2%) | 0.569 (F) |
| Cholesterol polyp | 12 (2.7%) | 5 (0.4%) | 0.001 (F) |
| Adenomyomatosis | 10 (2.2%) | 30 (2.4%) | 0.805 (P) |
| Fibrosis | 6 (1.3%) | 6 (0.5%) | 0.096 (F) |
| Gangrene | 14 (3.1%) | 9 (0.7%) | 0.001 (P) |
| Abscess | 5 (1.1%) | 3 (0.2%) | 0.036 (F) |
| Pyloric metaplasia | 15 (3.3%) | 57(4.6%) | 0.250 (P) |
| Intestinal metaplasia | 3 (0.7%) | 15(1.2%) | 0.430 (F) |
| Dysplasia | 0 (0.0%) | 4 (0.3%) | 0.579 (F) |
| Cancer | 0 (0.0%) | 2 (0.2%) | 1.000 (F) |
| Number of patients | 451 | 1,238 |
(P) Pearson’s test; (F) Fisher’s test;
= statistically significant difference.
Analysis of the gallbladder histological alterations according to age.
| ≤ 40 n (%) | 41–60 n (%) | > 60 n (%) | p | |
|---|---|---|---|---|
| Cholesterolosis | 96 (19.3%) | 143 (19.4%) | 66 (14.4%) | 0.063 |
| Acute cholecystitis | 34 ( 6.8%) | 85 (11.5%) | 55 (12.0%) | 0.011 |
| Xanthogranulomatous cholecystitis | 8 (1.6%) | 10 (0.1%) | 11 (2.4%) | 0.390 |
| Sclero-atrophic gallbladder | 2 (0.4%) | 15 (2.0%) | 3 (2.6%) | 0.016 |
| Hyperplasic polyp | 1 (0.2%) | 0 (0.0%) | 2 (0.4%) | 0.215 |
| Cholesterol polyp | 4 (0.8%) | 10 (0.1%) | 3 (2.6%) | 0.435 |
| Adenomyomatosis | 8 (1.6%) | 12 (1.6%) | 20 (4.3%) | 0.004 |
| Fibrosis | 2 (0.4%) | 6 (0.8%) | 4 (0.8%) | 0.623 |
| Gangrene | 2 (0.4%) | 9 (1.2%) | 12 (2.6%) | 0.012 |
| Abscess | 0 (0.0%) | 4 (0.5%) | 4 (0.8%) | 0.136 |
| Pyloric metaplasia | 19 (3.8%) | 31 (4.2%) | 22 (4.8%) | 0.754 |
| Intestinal metaplasia | 5 (1.0%) | 6 (0.8%) | 7 (1.5%) | 0.497 |
| Dysplasia | 1 (0.2%) | 1 (0.1%) | 2 (0.4%) | 0.570 |
| Cancer | 0 (0.0%) | 1 (0.1%) | 1 (0.2%) | 0.608 |
| Number of patients | 495 | 737 | 457 |
= statistically significant difference.
Average age of occurrence of each gallbladder histological alteration studied+
| Average age with an alteration (yr) | Average age without an alteration (yr) | p | |
|---|---|---|---|
| Cholesterolosis | 48.5 ± 14 | 50.4 ± 15 | 0.050 |
| Acute cholecystitis | 53.7 ± 14 | 49.6 ± 15 | 0.001 |
| Xanthogranulomatous cholecystitis | 52.5 ± 17 | 50.0 ± 15 | 0.384 |
| Sclero-atrophic gallbladder | 53.7 ± 10 | 50.0 ± 15 | 0.117 |
| Hyperplasic polyp | 56.7 ± 25 | 50.0 ± 15 | 0.446 |
| Cholesterol polyp | 50.2 ± 13 | 50.0 ± 15 | 0.955 |
| Adenomyomatosis | 56.1 ± 15 | 49.9 ± 15 | 0.010 |
| Fibrosis | 51.9 ± 15 | 50.0 ± 15 | 0.664 |
| Gangrene | 60.9 ± 14 | 49.9 ± 15 | 0.001 |
| Abscess | 62.4 ± 12 | 50.0 ± 15 | 0.020 |
| Pyloric metaplasia | 50.6 ± 15 | 50.0 ± 15 | 0.744 |
| Intestinal metaplasia | 53.9 ± 14 | 50.0 ± 15 | 0.275 |
| Dysplasia | 56.8 ± 24 | 50.0 ± 15 | 0.618 |
| Cancer | 60.0 ± 27 | 50.0 ± 15 | 0.350 |
Continuous variables are described as mean ± SEM (standard error of mean); the p value was derived using student’s T-test;
= statistically significant difference.
Analysis of the histological alterations according to the presence or absence of symptoms
| Asymptomatic patients n (%) | Symptomatic patients n (%) | p | |
|---|---|---|---|
| Cholesterolosis | 34 (23.1%) | 271 (17.6%) | 0.094 (P) |
| Acute cholecystitis | 4 (2.7%) | 170 (11.0%) | 0.002 (P) |
| Xanthogranulomatous cholecystitis | 3 (2.0%) | 26 (1.7%) | 0.735 (F) |
| Sclero-atrophic gallbladder | 2 (1.4%) | 18 (1.2%) | 0.691 (F) |
| Hyperplasic polyp | 1 (0.7%) | 2 (0.1%) | 0.239 (F) |
| Cholesterol polyp | 4 (2.7%) | 13 (0.8%) | 0.054 (F) |
| Adenomyomatosis | 3 (2.0%) | 37 (2.4%) | 1.000 (F) |
| Fibrosis | 2 (1.4%) | 10 (0.6%) | 0.281 (F) |
| Gangrene | 1 (0.7%) | 22 (1.4%) | 0.715 (F) |
| Abscess | 0 (0.0%) | 8 (0.5%) | 1.000 (F) |
| Pyloric metaplasia | 7 (4.8%) | 65 (4.2%) | 0.754 (P) |
| Intestinal metaplasia | 1 (0.7%) | 17 (1.1%) | 1.000 (F) |
| Dysplasia | 2 (1.4%) | 2 (0.1%) | 0.040 (F) |
| Cancer | 0 (0.0%) | 2 (0.1%) | 1.000 (F) |
| Number of patients | 147 | 1,542 |
(P) indicates Pearson’s test; (F) indicates Fisher’s test;
= statistically significant difference.
Analysis of gallbladder histological alterations and metaplastic alterations
| Pyloric metaplasia n / p | Intestinal metaplasia n / p | |
|---|---|---|
| Cholesterolosis | 12 / 0.754 (P) | 0 / 0.580 (F) |
| Acute cholecystitis | 2 / 0.320 (P) | 5 / 0.310 (F) |
| Xanthogranulomatous cholecystitis | 1 / 1.000 (F) | 0 / 1.000 (F) |
| Sclero-atrophic gallbladder | 1 / 0.584 (F) | 0 / 0.641 (P) |
| Hyperplasic polyp | 0 / 1.000 (F) | 0 / 1.000 (F) |
| Cholesterol polyp | 0 / 1.000 (F) | 0 / 1.000 (F) |
| Adenomyomatosis | 4 / 0.087 (F) | 4 / 0.001 (F) |
| Fibrosis | 0 / 1.000 (F) | 0 / 1.000 (F) |
| Gangrene | 0 / 0.308 (P) | 0 / 0.616 (P) |
| Abscess | 0 / 1.000 (F) | 0 / 1.000 (F) |
| Pyloric metaplasia | ---------- | 9 / 0.000 (F) |
| Dysplasia | 2 / 0.010 (F) | 2 / 0.001 (F) |
| Cancer | 2 / 0.002 (F) | 2 / 0.000 (F) |
(P) indicates Pearson’s test; (F) indicates Fisher’s test;
= statistically significant difference